Axicabtagene ciloleucel (Yescarta, Kite) is indicated for 'the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B‑cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy'.
The dosage schedule is available in the summary of product characteristics for axicabtagene ciloleucel.
The company has a commercial arrangement. This makes axicabtagene ciloleucel available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.